Vincent Goffin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6233999/publications.pdf

Version: 2024-02-01

81839 79644 5,911 111 39 73 citations h-index g-index papers 116 116 116 5383 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hematopoietic PBXâ€interacting protein is a novel regulator of mammary epithelial cell differentiation. FEBS Journal, 2022, 289, 1575-1590.	2.2	5
2	Prostate luminal progenitor cells: from mouse to human, from health to disease. Nature Reviews Urology, 2022, 19, 201-218.	1.9	12
3	Sex-dependent pain trajectories induced by prolactin require an inflammatory response for pain resolution. Brain, Behavior, and Immunity, 2022, 101, 246-263.	2.0	9
4	High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers, 2022, 14, 1623.	1.7	5
5	Growth Hormone Receptor (GHR) is overexpressed in low EGFR expressing glioblastoma and promotes tumor growth. , 2022, , .		O
6	Meningeal <scp>CGRP</scp> â€Prolactin Interaction Evokes Femaleâ€Specific Migraine Behavior. Annals of Neurology, 2021, 89, 1129-1144.	2.8	46
7	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS ONE, 2021, 16, e0252040.	1.1	8
8	Abstract 2038: A non-canonical, cell-autonomous STING function protects breast cancer cells from intrinsic and genotoxic-induced DNA instability., 2021,,.		0
9	STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway. Oncogene, 2021, 40, 6627-6640.	2.6	26
10	Neuroendocrine Mechanisms Governing Sex Differences in Hyperalgesic Priming Involve Prolactin Receptor Sensory Neuron Signaling. Journal of Neuroscience, 2020, 40, 7080-7090.	1.7	34
11	Positive association between progestins and the evolution of multiple fibroadenomas in 72 women. Endocrine Connections, 2020, 9, 570-577.	0.8	5
12	Abstract P2-05-06: Nuclear STING localization induces chemoresistance in breast cancer., 2020,,.		0
13	STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice. Cancers, 2019, 11, 929.	1.7	12
14	Prolactin Regulates Pain Responses via a Female-Selective Nociceptor-Specific Mechanism. IScience, 2019, 20, 449-465.	1.9	56
15	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Cancer Research, 2019, 79, 5316-5327.	0.4	36
16	Prolactin receptor expression in mouse dorsal root ganglia neuronal subtypes is sexâ€dependent. Journal of Neuroendocrinology, 2019, 31, e12759.	1.2	34
17	Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle formation. Scientific Reports, 2019, 9, 5878.	1.6	17
18	Combined Sabal and Urtica Extracts (WS \hat{A}^{\otimes} 1541) Exert Anti-proliferative and Anti-inflammatory Effects in a Mouse Model of Benign Prostate Hyperplasia. Frontiers in Pharmacology, 2019, 10, 311.	1.6	18

#	Article	IF	Citations
19	Prolactin and its receptor as therapeutic targets in glioblastoma multiforme. Scientific Reports, 2019, 9, 19578.	1.6	19
20	Paul Kelly, PhD (1943–2018). Pituitary, 2019, 22, 1-3.	1.6	0
21	JAK2/STAT5 Pathway Mediates Prolactin-Induced Apoptosis of Lactotropes. Neuroendocrinology, 2019, 108, 84-97.	1.2	17
22	ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage. Endocrinology, 2018, 159, 907-930.	1.4	8
23	Novel reagents for human prolactin research: large-scale preparation and characterization of prolactin receptor extracellular domain, non-pegylated and pegylated prolactin and prolactin receptor antagonist. Protein Engineering, Design and Selection, 2018, 31, 7-16.	1.0	8
24	Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα+ Mammary Carcinomas. Cancer Research, 2018, 78, 1672-1684.	0.4	21
25	$17\hat{l}^2$ -Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes. Journal of the Endocrine Society, 2018, 2, 293-309.	0.1	9
26	Do dietary calcium and vitamin D matter in men with prostate cancer?. Nature Reviews Urology, 2018, 15, 453-461.	1.9	18
27	Abstract 919: Endogenous STING inhibition induces breast cancer cell death. , 2018, , .		0
28	Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. , 2017, 179, 111-126.		57
29	A rare castrationâ€resistant progenitor cell population is highly enriched in Ptenâ€null prostate tumours. Journal of Pathology, 2017, 243, 51-64.	2.1	27
30	Alpha 2 -adrenoceptor agonists trigger prolactin signaling in breast cancer cells. Cellular Signalling, 2017, 34, 76-85.	1.7	25
31	Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. Cancer Research, 2017, 77, 355-365.	0.4	38
32	Abstract 90: STING colocalizes with gamma-H2AX upon treatment of breast cancer cells with genotoxics: A new role in DNA repair., 2017,,.		0
33	Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents. Oncotarget, 2016, 7, 77205-77224.	0.8	55
34	Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4449-4460.	1.8	10
35	The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation. Rheumatology, 2016, 55, 2248-2259.	0.9	29
36	Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine, 2016, 7, 35-49.	2.7	39

#	Article	IF	Citations
37	The Role of Prolactin in Bone Metastasis and Breast Cancer Cell–Mediated Osteoclast Differentiation. Journal of the National Cancer Institute, 2016, 108, djv338.	3.0	44
38	Abstract B56: Prolactin promotes breast cancer to bone metastasis and breast cancer cell-mediated osteoclast differentiation. , 2016, , .		0
39	Abstract 2138: Functional evaluation of interferon/STAT1 pathway activation in response to genotoxic treatment. , 2016, , .		0
40	Hypothalamic Prolactin Regulation of Luteinizing Hormone Secretion in the Female Rat. Endocrinology, 2015, 156, 2880-2892.	1.4	10
41	Intrinsically disordered cytoplasmic domains of two cytokine receptors mediate conserved interactions with membranes. Biochemical Journal, 2015, 468, 495-506.	1.7	68
42	Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: Potential implications in breast tumorigenesis. Molecular and Cellular Endocrinology, 2015, 401, 173-188.	1.6	14
43	Prolactin-Induced Prostate Tumorigenesis. Advances in Experimental Medicine and Biology, 2015, 846, 221-242.	0.8	29
44	The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications. Expert Opinion on Therapeutic Targets, 2015, 19, 1229-1244.	1.5	54
45	Antiâ€inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate, 2015, 75, 706-722.	1.2	36
46	A Residue Quartet in the Extracellular Domain of the Prolactin Receptor Selectively Controls Mitogen-activated Protein Kinase Signaling. Journal of Biological Chemistry, 2015, 290, 11890-11904.	1.6	4
47	Minireview: Prolactin Regulation of Adult Stem Cells. Molecular Endocrinology, 2015, 29, 667-681.	3.7	28
48	Human and murine prostate basal/stem cells are not direct targets of prolactin. General and Comparative Endocrinology, 2015, 220, 133-142.	0.8	4
49	High Milk Consumption Does Not Affect Prostate Tumor Progression in Two Mouse Models of Benign and Neoplastic Lesions. PLoS ONE, 2015, 10, e0125423.	1.1	19
50	Abstract A103: Cell-autonomous activation of the interferon/STAT1 pathway in response to genotoxic treatment. , 2015, , .		0
51	Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting. Prostate, 2014, 74, 732-742.	1.2	16
52	Impaired Islet Function in Commonly Used Transgenic Mouse Lines due to Human Growth Hormone Minigene Expression. Cell Metabolism, 2014, 20, 979-990.	7.2	145
53	Prolactin-Induced Prostate Tumorigenesis Links Sustained Stat5 Signaling with the Amplification of Basal/Stem Cells and Emergence of Putative Luminal Progenitors. American Journal of Pathology, 2014, 184, 3105-3119.	1.9	36
54	Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility. Journal of Endocrinology, 2014, 222, 341-350.	1.2	8

#	Article	IF	CITATIONS
55	Calcium channels, external calcium concentration and cell proliferation. European Journal of Pharmacology, 2014, 739, 19-25.	1.7	53
56	Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis, 2014, 35, 795-806.	1.3	61
57	The Structure and Oligomericity of the Transmembrane Domain of Cytokine Receptors is Modulated by the Protein/Lipid Ratio. Biophysical Journal, 2014, 106, 21a.	0.2	0
58	Prolactin Induces Apoptosis of Lactotropes in Female Rodents. PLoS ONE, 2014, 9, e97383.	1.1	25
59	Prolactin regulates transcription of the ion uptake Na+/Clâ^' cotransporter (ncc) gene in zebrafish gill. Molecular and Cellular Endocrinology, 2013, 369, 98-106.	1.6	53
60	Tif $1\hat{1}^3$ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (Cambridge), 2013, 140, 167-175.	1.2	24
61	Fetal Pancreas Transplants Are Dependent on Prolactin for Their Development and Prevent Type 1 Diabetes in Syngeneic but Not Allogeneic Mice. Diabetes, 2013, 62, 1646-1655.	0.3	6
62	Use of Prolactin Receptor Antagonist to Better Understand Prolactin Regulation of Pituitary Homeostasis. Neuroendocrinology, 2013, 98, 171-179.	1.2	29
63	Tumour Necrosis Factor Alpha, Interferon Gamma and Substance P Are Novel Modulators of Extrapituitary Prolactin Expression in Human Skin. PLoS ONE, 2013, 8, e60819.	1.1	25
64	Prolactin as an osmoregulatory hormone in zebrafish: transcriptional regulation of a Na + /Cl â^' cotransporter (ncc) in the gill. FASEB Journal, 2013, 27, 714.6.	0.2	0
65	Is prolactin involved in the evolution of atherothrombotic disease?. Expert Review of Endocrinology and Metabolism, 2012, 7, 345-361.	1.2	3
66	The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells. International Journal of Oncology, 2012, 41, 2285-2295.	1.4	17
67	Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E356-E364.	1.8	37
68	Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?. Journal of Cellular and Molecular Medicine, 2012, 16, 2035-2048.	1.6	52
69	The WSXWS Motif in Cytokine Receptors IsÂa Molecular Switch Involved in Receptor Activation: Insight from Structures of the Prolactin Receptor. Structure, 2012, 20, 270-282.	1.6	73
70	Meeting report: the 2012 FASEB Science Research Conference "The growth hormone/prolactin family in biology and disease" A novel biannual rendez-vous in the endocrinology landscape. Pediatric Endocrinology Reviews, 2012, 10, 243-5.	1.2	1
71	Prolactin regulation of the prostate gland: a female player in a male game. Nature Reviews Urology, 2011, 8, 597-607.	1.9	78
72	Investigation of Prolactin Receptor Activation and Blockade Using Time-Resolved Fluorescence Resonance Energy Transfer. Frontiers in Endocrinology, 2011, 2, 29.	1.5	15

#	Article	IF	Citations
73	Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia. European Journal of Neuroscience, 2011, 34, 745-754.	1.2	30
74	Development of prolactin receptor antagonists with reduced pHâ€dependence of receptor binding. Journal of Molecular Recognition, 2011, 24, 533-547.	1.1	6
75	The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis?. Journal of Endocrinology, 2011, 208, 107-117.	1.2	45
76	Prolactin and Human Tumourogenesis. Journal of Neuroendocrinology, 2010, 22, 771-777.	1.2	52
77	Mind the (Gender) Gap: Does Prolactin Exert Gender and/or Site-Specific Effects on the Human Hair Follicle?. Journal of Investigative Dermatology, 2010, 130, 886-891.	0.3	40
78	Crystal Structure of an Affinity-matured Prolactin Complexed to Its Dimerized Receptor Reveals the Topology of Hormone Binding Site 2. Journal of Biological Chemistry, 2010, 285, 8422-8433.	1.6	59
79	Prolactinâ€"a novel neuroendocrine regulator of human keratin expression <i>in situ</i> . FASEB Journal, 2010, 24, 1768-1779.	0.2	63
80	Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15199-15204.	3.3	87
81	Identification of Gain-of-Function Variants of the Human Prolactin Receptor. Methods in Enzymology, 2010, 484, 329-355.	0.4	15
82	Characterization of Two Constitutively Active Prolactin Receptor Variants in a Cohort of 95 Women with Multiple Breast Fibroadenomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 271-279.	1.8	44
83	Structural Characterization of the Stem–Stem Dimerization Interface between Prolactin Receptor Chains Complexed with the Natural Hormone. Journal of Molecular Biology, 2010, 404, 112-126.	2.0	45
84	Prolactin: an emerging force along the cutaneous–endocrine axis. Trends in Endocrinology and Metabolism, 2010, 21, 569-577.	3.1	52
85	Rational Design of Competitive Prolactin/Growth Hormone Receptor Antagonists. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 105-117.	1.0	47
86	Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14533-14538.	3.3	78
87	Autocrine Prolactin Promotes Prostate Cancer Cell Growth via Janus Kinase-2-Signal Transducer and Activator of Transcription-5a/b Signaling Pathway. Endocrinology, 2007, 148, 3089-3101.	1.4	114
88	Development of Prolactin Receptor Antagonists: Same Goal, Different Ways. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 41-52.	0.7	6
89	Autocrine Prolactin Inhibits Human Uterine Decidualization: A Novel Role for Prolactin 1. Biology of Reproduction, 2007, 76, 777-783.	1.2	45
90	Structural and Thermodynamic Bases for the Design of Pure Prolactin Receptor Antagonists. Journal of Biological Chemistry, 2007, 282, 33118-33131.	1.6	66

#	Article	lF	CITATIONS
91	Prolactin Modulates TRPV1 in Female Rat Trigeminal Sensory Neurons. Journal of Neuroscience, 2006, 26, 8126-8136.	1.7	120
92	Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. Clinical Endocrinology, 2006, 65, 146-153.	1.2	24
93	Human Macroprolactin Displays Low Biological Activity via Its Homologous Receptor in a New Sensitive Bioassay. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1048-1055.	1.8	76
94	Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. Journal of Endocrinology, 2006, 190, 271-285.	1.2	32
95	Benign Breast Diseases. Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 325-335.	1.0	57
96	Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists. Endocrine Reviews, 2005, 26, 400-422.	8.9	197
97	Prolactin Specifically Activates Signal Transducer and Activator of Transcription 5b in Neuroendocrine Dopaminergic Neurons. Endocrinology, 2005, 146, 5112-5119.	1.4	68
98	Solution Structure of Human Prolactin. Journal of Molecular Biology, 2005, 351, 810-823.	2.0	105
99	New Homologous Bioassays for Human Lactogens Show That Agonism or Antagonism of Various Analogs Is a Function of Assay Sensitivity. Endocrine, 2003, 20, 177-190.	2.2	43
100	Development of New Prolactin Analogs Acting as Pure Prolactin Receptor Antagonists. Pituitary, 2003, 6, 89-95.	1.6	16
101	Development of Pure Prolactin Receptor Antagonists. Journal of Biological Chemistry, 2003, 278, 35988-35999.	1.6	105
102	Implications of Multiple Phenotypes Observed in Prolactin Receptor Knockout Mice. Frontiers in Neuroendocrinology, 2001, 22, 140-145.	2.5	75
103	Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene, 2000, 19, 4695-4705.	2.6	90
104	From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models. Genetic Analysis, Techniques and Applications, 1999, 15, 189-201.	1.5	72
105	Homodimerization of IL-2 receptor \hat{l}^2 chain is necessary and sufficient to activate Jak2 and dowstream signaling pathways. FEBS Letters, 1998, 421, 32-36.	1.3	12
106	Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice. Endocrine Reviews, 1998, 19, 225-268.	8.9	1,639
107	The prolactin/growth hormone receptor family: structure/function relationships. Journal of Mammary Gland Biology and Neoplasia, 1997, 2, 7-17.	1.0	129
108	Sequence-Function Relationships Within the Expanding Family of Prolactin, Growth Hormone, Placental Lactogen, and Related Proteins in Mammals*. Endocrine Reviews, 1996, 17, 385-410.	8.9	238

VINCENT GOFFIN

#	Article	IF	CITATIONS
109	Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay. Journal of Biological Chemistry, 1996, 271, 16573-16579.	1.6	100
110	Characterization of Lactogen Receptor-binding Site 1 of Human Prolactin. Journal of Biological Chemistry, 1996, 271, 14353-14360.	1.6	39
111	Prolactin Regulates Pain Responses Via a Female-Selective Nociceptor-Specific Mechanism. SSRN Electronic Journal, 0, , .	0.4	O